Metadata supporting the article: The impact of mammographic screening on the subsequent breast cancer risk associated with biopsy-proven benign breast disease
Creators: name: Beca, Francisco
name: Oh, Hannah
name: Collins, Laura C.
name: Rulla M. Tamimi
name: Schnitt, Stuart J.
Publisher: name: figshare
Year: 2021
Subjects: subject: Cancer
subject: 10402 Biostatistics
subject: FOS: Mathematics
subject: FOS: Mathematics
subject: Medicine
subject: 111202 Cancer Diagnosis
subject: FOS: Clinical medicine
subject: FOS: Clinical medicine
subject: 119999 Medical and Health Sciences not elsewhere classified
subject: FOS: Other medical sciences
subject: FOS: Other medical sciences

description: Data on the risk of breast cancer following a benign breast disease (BBD) diagnosis were derived predominantly from populations of women biopsied before the widespread use of mammographic screening and in whom these lesions were mostly incidental findings. Whether or not similar risk associations are seen when these lesions are detected in mammographically screened populations is unknown. To address this, the authors examined the variation in BBD and breast cancer risk associations by the calendar time of BBD diagnosis (pre- vs. post-mammographic era [before vs. 1985 and after]) in a nested case-control study within the Nurses’ Health Study (NHS) and NHSII BBD subcohorts (488 cases; 1,908 controls).<br> <b>Data access: </b>The data that support the findings of this study are available from the Nurses’ Health Studies but restrictions apply to the availability of these data, and so they are not publicly available. However, the data are available from the corresponding author, Dr. Stuart Schnitt, email address: sschnitt@bwh.harvard.edu, upon reasonable request, and with the permission of Nurses’ Health Studies External Advisory Board. Additional data sharing information and policy details can be accessed at http://www.nurseshealthstudy.org/researchers.<br> <b> </b> <b>Study approval and patient consent: </b>The study protocol was approved by the institutional review boards of the Brigham and Women’s Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required. Completion of the self-administered questionnaire was presumed to imply informed consent. This study complies with The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.<br> <b>Study aims and methodology: </b>Breast cancer risks associated with BBD subtypes were reported by studies that followed up large cohorts of women undergoing breast biopsies with different baseline characteristics and indications for biopsies, possibly reducing the ability to generalize these results to women undergoing breast biopsies for abnormalities detected by screening mammography. This observation not only has potential consequences for individual patient counseling but could affect some of today’s best-known breast cancer risk prediction models that use features like the number of biopsies and BBD subtype. While these differences have been recognized in terms of breast cancer risk development models, this is the first study to date that has examined whether the previously estimated BBD-breast cancer risk associations are still valid after the widespread introduction of screening mammography. This study is a nested case-control study within the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHS II) cohorts with biopsy-confirmed BBD. The NHS is an ongoing prospective cohort study that began in 1976, when 121,700 female registered nurses between the ages of 30 and 55 years completed a mailed questionnaire. The NHS II consists of 116,609 female registered nurses who were between the ages of 25 and 42 years when the study began in 1989. In both cohorts, participants have been followed via biennial questionnaires that provide information on lifestyle factors (body mass index (BMI), reproductive history, postmenopausal hormone (PMH) use, and alcohol use) and incident disease. The authors performed logistic regression analysis, adjusting for matching factors and potential confounders, to estimate odds ratio (ORs) and 95% confidence interval (CI) for the association between BBD subtype (non-proliferative, proliferative without atypia, proliferative with atypical hyperplasia) and subsequent breast cancer risk. For more details on the methodology, please read the related article.<br> <b>Data file description: table1_bbd.sas</b> is in SAS file format and supports table 1. <b>table2.sas</b> is in SAS file format and supports table 2. <b>table3.sas</b> is in SAS file format and supports table 3. <b>suppltable1.sas</b> is in SAS file format and supports supplementary table 1. <b>suppltable2.sas</b> is in SAS file format and supports supplementary table 2. <b>suppltable3.sas</b> is in SAS file format and supports supplementary table 3. <b>suppltable4.sas</b> is in SAS file format and supports supplementary table 4.<br> <b>Software needed to access datasets</b>: The datasets listed above can be accessed using the SAS statistical software. <b> </b> <b> </b> <b> </b> <b> </b>